TB-500 (Thymosin Beta-4 Fragment)

Not FDA approvedTissue Repair ResearchRecovery & tissue repairGH axis & hormonesImmune & gut
6.6

Worth trying, BioHarmony verdict

BioHarmony score 6.6 out of 10

TB-500 is a synthetic LKKTETQ fragment marketed for soft-tissue repair, but most human evidence is on full-length topical thymosin beta-4: Sosne 2023 reported corneal healing in 6 of 10 RGN-259 subjects versus 1 of 8 placebo.

Read full report

What is TB-500 (Thymosin Beta-4 Fragment)?

TB-500 is the peptide-market name for a synthetic fragment commonly described as Ac-LKKTETQ, derived from the broader biology of thymosin beta-4. Most published human and animal literature is not on TB-500 itself. It is on full-length Tbeta4, a 43-amino-acid protein involved in actin dynamics, cell migration, angiogenesis, inflammation resolution, and tissue repair.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

How it is thought to work

G-actin monomer binding, cell migration support, angiogenesis signaling, inflammation modulation, matrix remodeling.

Safety watch-outs

  • Injection-site infection
  • Rapidly worsening swelling or pain

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for TB-500 (Thymosin Beta-4 Fragment) yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (8)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalNot FDA approved
CompoundingWithdrawn from Category 2 nomination; eligibility is not established

FDA identifies immunogenicity and peptide-impurity concerns for compounded TB-500 and says it has not identified human exposure data for the fragment.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.